Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 46.16B |
| Revenue (ttm) | 10.37B |
| Net Income (ttm) | 3.25B |
| Shares Out | n/a |
| EPS (ttm) | 28.96 |
| PE Ratio | 14.19 |
| Forward PE | 14.74 |
| Dividend | 2.01 (0.33%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 550 |
| Average Volume | 523 |
| Open | 600.04 |
| Previous Close | 599.41 |
| Day's Range | 598.51 - 618.23 |
| 52-Week Range | 477.01 - 1,041.12 |
| Beta | n/a |
| RSI | 61.19 |
| Earnings Date | Oct 28, 2025 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes
(RTTNews) - Formycon AG (FYB.DE), in collaboration with its license partners Klinge Biopharma GmbH and Valorum Biologics, has reached a settlement and entered into a license agreement with Regeneron P...
Notable Wednesday Option Activity: CVS, HOOD, REGN
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in CVS Health Corporation (Symbol: CVS), where a total volume of 38,300 contracts has been...
Wednesday's ETF Movers: FBT, BIZD
In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 3.7% on the day. Components of that ETF showing particular strength include shares...
Regeneron (REGN) Sees Stock Surge as Core Product Sales Rise
Regeneron (REGN) Sees Stock Surge as Core Product Sales Rise
REGN Makes Bullish Cross Above Critical Moving Average
In trading on Wednesday, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) crossed above their 200 day moving average of $610.84, changing hands as high as $611.39 per share. Regeneron Pharmace...
Regeneron: Growth Catalysts Incoming
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday...
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
CNBC's "Halftime Report" team detail their stock picks and final trades.
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
CNBC's "Halftime Report" team detail their stock picks and final trades.
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Regeneron: Strong R&D Pipeline Drives Growth Outlook
Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. S...
4 stocks to watch on Friday: META, COST, REGN, XOM
META, COST, REGN, XOM are the stocks to watch on Friday
FDA Expands Use of Regeneron's (REGN) Evkeeza for Young Children
FDA Expands Use of Regeneron's (REGN) Evkeeza for Young Children
Regeneron (REGN) Gains FDA Approval for Evkeeza Expansion to Younger Age Group
Regeneron (REGN) Gains FDA Approval for Evkeeza Expansion to Younger Age Group
Regeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drug
Regeneron (REGN) stock is in focus as the FDA approves a label expansion for Evkeeza its cholesterol therapy marketed with Ultragenyx (RARE). Read more here.
Regeneron Reports FDA Approval Extending Indication Of Evkeeza
(RTTNews) - Regeneron Pharmaceuticals (REGN) announced the FDA has approved Evkeeza ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children...
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit...
November 7th Options Now Available For Regeneron Pharmaceuticals (REGN)
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Sen...
What Does the Market Think About Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's (NYSE: REGN) short interest as a percent of float has risen 20.52% since its last report. According to exchange reported data, there are now 2.83 million shares sold short...
Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises
Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with ...
Noteworthy Tuesday Option Activity: HAL, PSKY, REGN
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Halliburton Company (Symbol: HAL), where a total volume of 142,416 contracts has been t...
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recomm...
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...